100 related articles for article (PubMed ID: 28070500)
21. Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection.
de Vries RD; Nieuwkoop NJ; Pronk M; de Bruin E; Leroux-Roels G; Huijskens EGW; van Binnendijk RS; Krammer F; Koopmans MPG; Rimmelzwaan GF
Vaccine; 2017 Jan; 35(2):238-247. PubMed ID: 27914742
[TBL] [Abstract][Full Text] [Related]
22. Influenza Anti-Stalk Antibodies: Development of a New Method for the Evaluation of the Immune Responses to Universal Vaccine.
Manenti A; Maciola AK; Trombetta CM; Kistner O; Casa E; Hyseni I; Razzano I; Torelli A; Montomoli E
Vaccines (Basel); 2020 Jan; 8(1):. PubMed ID: 31991681
[TBL] [Abstract][Full Text] [Related]
23. Universal monoclonal antibody-based influenza hemagglutinin quantitative enzyme-linked immunosorbent assay.
Chae W; Kim P; Hwang BJ; Seong BL
Vaccine; 2019 Mar; 37(11):1457-1466. PubMed ID: 30765169
[TBL] [Abstract][Full Text] [Related]
24. Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones.
He W; Mullarkey CE; Duty JA; Moran TM; Palese P; Miller MS
J Virol; 2015 Apr; 89(7):3610-8. PubMed ID: 25589655
[TBL] [Abstract][Full Text] [Related]
25. A Universal Influenza Virus Vaccine Candidate Tested in a Pig Vaccination-Infection Model in the Presence of Maternal Antibodies.
Sunwoo SY; Schotsaert M; Morozov I; Davis AS; Li Y; Lee J; McDowell C; Meade P; Nachbagauer R; García-Sastre A; Ma W; Krammer F; Richt JA
Vaccines (Basel); 2018 Sep; 6(3):. PubMed ID: 30223475
[TBL] [Abstract][Full Text] [Related]
26. Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts.
Nachbagauer R; Salaun B; Stadlbauer D; Behzadi MA; Friel D; Rajabhathor A; Choi A; Albrecht RA; Debois M; García-Sastre A; Rouxel RN; Sun W; Palese P; Mallett CP; Innis BL; Krammer F; Claeys C
NPJ Vaccines; 2019; 4():51. PubMed ID: 31839997
[TBL] [Abstract][Full Text] [Related]
27. Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies.
Wang W; Butler EN; Veguilla V; Vassell R; Thomas JT; Moos M; Ye Z; Hancock K; Weiss CD
J Virol Methods; 2008 Nov; 153(2):111-9. PubMed ID: 18722473
[TBL] [Abstract][Full Text] [Related]
28. Measuring the neutralization potency of influenza A virus hemagglutinin stalk/stem-binding antibodies in polyclonal preparations by microneutralization assay.
He W; Mullarkey CE; Miller MS
Methods; 2015 Nov; 90():95-100. PubMed ID: 25957674
[TBL] [Abstract][Full Text] [Related]
29. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.
Kim SM; Kim YI; Park SJ; Kim EH; Kwon HI; Si YJ; Lee IW; Song MS; Choi YK
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077631
[TBL] [Abstract][Full Text] [Related]
30. Universal Influenza Virus Vaccines That Target the Conserved Hemagglutinin Stalk and Conserved Sites in the Head Domain.
Krammer F; Palese P
J Infect Dis; 2019 Apr; 219(Suppl_1):S62-S67. PubMed ID: 30715353
[TBL] [Abstract][Full Text] [Related]
31. An Optimized Method for the Production Using PEI, Titration and Neutralizationof SARS-CoV Spike Luciferase Pseudotypes.
Carnell G; Grehan K; Ferrara F; Molesti E; Temperton N
Bio Protoc; 2017 Aug; 7(16):e2514. PubMed ID: 34541175
[TBL] [Abstract][Full Text] [Related]
32. Dissecting the hemagglutinin head and stalk-specific IgG antibody response in healthcare workers following pandemic H1N1 vaccination.
Tete SM; Krammer F; Lartey S; Bredholt G; Wood J; Skrede S; Cox RJ
NPJ Vaccines; 2016; 1():16001-. PubMed ID: 29250435
[TBL] [Abstract][Full Text] [Related]
33. A mutation in the receptor binding site enhances infectivity of 2009 H1N1 influenza hemagglutinin pseudotypes without changing antigenicity.
Wang W; Castelán-Vega JA; Jiménez-Alberto A; Vassell R; Ye Z; Weiss CD
Virology; 2010 Nov; 407(2):374-80. PubMed ID: 20869738
[TBL] [Abstract][Full Text] [Related]
34. Rapid and reliable universal cloning of influenza A virus genes by target-primed plasmid amplification.
Stech J; Stech O; Herwig A; Altmeppen H; Hundt J; Gohrbandt S; Kreibich A; Weber S; Klenk HD; Mettenleiter TC
Nucleic Acids Res; 2008 Dec; 36(21):e139. PubMed ID: 18832366
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of Preexisting Anti-Hemagglutinin Stalk Antibody as a Correlate of Protection in a Healthy Volunteer Challenge with Influenza A/H1N1pdm Virus.
Park JK; Han A; Czajkowski L; Reed S; Athota R; Bristol T; Rosas LA; Cervantes-Medina A; Taubenberger JK; Memoli MJ
mBio; 2018 Jan; 9(1):. PubMed ID: 29362240
[TBL] [Abstract][Full Text] [Related]
36. Integrase Defective Lentiviral Vector as a Vaccine Platform for Delivering Influenza Antigens.
Gallinaro A; Borghi M; Bona R; Grasso F; Calzoletti L; Palladino L; Cecchetti S; Vescio MF; Macchia D; Morante V; Canitano A; Temperton N; Castrucci MR; Salvatore M; Michelini Z; Cara A; Negri D
Front Immunol; 2018; 9():171. PubMed ID: 29459873
[TBL] [Abstract][Full Text] [Related]
37. Hemagglutinin Stalk- and Neuraminidase-Specific Monoclonal Antibodies Protect against Lethal H10N8 Influenza Virus Infection in Mice.
Wohlbold TJ; Chromikova V; Tan GS; Meade P; Amanat F; Comella P; Hirsh A; Krammer F
J Virol; 2016 Jan; 90(2):851-61. PubMed ID: 26512088
[TBL] [Abstract][Full Text] [Related]
38. Seasonal influenza vaccination is the strongest correlate of cross-reactive antibody responses in migratory bird handlers.
Oshansky CM; Wong SS; Jeevan T; Smallwood HS; Webby RJ; Shafir SC; Thomas PG
mBio; 2014 Dec; 5(6):e02107. PubMed ID: 25491354
[TBL] [Abstract][Full Text] [Related]
39. A novel humanized antibody neutralizes H5N1 influenza virus via two different mechanisms.
Tan Y; Ng Q; Jia Q; Kwang J; He F
J Virol; 2015 Apr; 89(7):3712-22. PubMed ID: 25609802
[TBL] [Abstract][Full Text] [Related]
40. A vesicular stomatitis pseudovirus expressing the surface glycoproteins of influenza A virus.
Cheresiz SV; Kononova AA; Razumova YV; Dubich TS; Chepurnov AA; Kushch AA; Davey R; Pokrovsky AG
Arch Virol; 2014 Oct; 159(10):2651-8. PubMed ID: 24888312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
